Theriva Biologics Aktie Logo
US87164U5083

Theriva Biologics Aktie

Ins Portfolio
60% Chancen, 40% Gelassenheit. Aktien und Anleihen in einem LifeStrategy ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

 Anzeige

Prognose

Kaufen
  0
Halten
  1
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

    - VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial -» Mehr auf globenewswire.com


  • Theriva Biologics Announces Closing of $7.5 Million Public Offering

    ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the closing of its previously announced “reasonable best efforts” public offering of 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the “Offering”). The Company received aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants have an exercise price of $1.10 per share, became exercisable immediately upon issuance and expire five years from the issuance date.» Mehr auf globenewswire.com


  • Theriva Biologics Announces Pricing of $7.5 Million Public Offering

    ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its “reasonable best efforts” public offering for the purchase and sale of up to 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the “Offering”). The Company expects to receive aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $1.10 per share, will be exercisable immediately and will expire five years from the issuance date.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Theriva Biologics Aktie einen Umsatz von 0,00 und ein Nettoeinkommen von 4,00 Mio
(EUR)März 2025
YOY
Umsatz0,00-
Bruttoeinkommen0,00100,00%
Nettoeinkommen4,00 Mio16,48%
EBITDA4,08 Mio17,68%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+3,38 Mio
Anzahl Aktien
8,19 Mio
52 Wochen-Hoch/Tief
+6,35 - +0,35
DividendenNein
Beta
0,83
KGV (PE Ratio)
0,05
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
+0,08
KUV (PS Ratio)
+25,04

Unternehmensprofil

Name
Theriva Biologics Aktie
CEO
Steven A. Shallcross CPA
Mitarbeiter20
🍪

Parqet nutzt Cookies.Erfahre Mehr